【作者】 张清媛； 赵曙； 孙文洲； 马文杰； 李洪滨； 赵睿；

【Author】 ZHAO Shu,ZHANG Qingyuan,SUN Wenzhou,ZHAO Rui,LI Hongbin.Medical WardⅢ,The Tumour Hospital of Harbin Medical Univerdity,Harbin 150081,China

【机构】 哈尔滨医科大学附属肿瘤医院内三科；

【摘要】 目的观察吉西他滨联合顺铂和甲强龙(GEM-P)对于复发或者难治性的来源于T细胞的非霍奇金淋巴瘤的疗效和毒副反应。方法11例复发或者难治性的T细胞非霍奇金淋巴瘤患接受了至2个周期以上的化疗,具体方法为吉西他滨1000mg/m~2,D1,8,15静脉滴注;顺铂75mg/m~2,D15静脉滴注;甲强龙1g,D1-3静脉滴注,每4周为一个化疗周期。结果11例患者当中,2例获的了完全缓解(CR),占18.2%;6例达部分缓解(PR),占54.5%;总有效率(ORR)为72.7%。5例具有B症状的患者3例症状消失,1例明显改善,1例无变化。化疗主要的毒副作用为骨髓抑制、肝功能损害和胃肠道反应,极少数出现Ⅳ度骨髓抑制。结论吉西他滨联合顺铂和甲强龙对于复发或者难治性T细胞非霍奇金淋巴瘤患者有较好的近期疗效,能够显著的改善患者的症状而且具有较好的耐受性,但是远期疗效有待于进一步验证。更多还原

【Abstract】 Objective To evaluate the therapeutic effects and adverse reactions of combined gemcitabine,cisplatin and methylprednisolone in the treatment of relapsed or refractory T-cell non-Hodgkin’slymphoma.Methods Eleven patients with histologically confirmed relapsed or refractory T-cell non-Hodgkin’s lymphoma were included in our study,all the patients were treated with GEM-P regimen at least two cycles.Gemcitabine was given on D1,8,15 of a four weeks schedule at a dose of 1000mg/m~2 intravenously over 30 minutes,cisplation was given on D15 at a dose of 75mg/m~2 intravenously and methylprednisolone on D1-3 at a dose of 1g.Results Of 11 patients,the complete respose(CR) rate,partial response(PR) rate and overall response(OR) rate were 18.2%(2 patients),54.5%(6 patients) and 72.7%(8 patients) respectively. There were five patients having B symptoms in eleven patients,of them three patients’ symptoms disappeared,one patients was alleviated of B symptoms and one patients had no change. The mainadverse reactions included myelosuppression,liver function damage and mild gastrointestinal reactions in most patients and severe bone marrow depression in very few patients. Conclusion The GEM-P combined chemotherapty regiment had a good short-term therapeutic effect on patients with relapsed or refractory T-cell non-Hodgkin’s lymphoma and could be tolerated, but long-term effect needs further verification.更多还原